US Market In Pulmonx' Sights Nine Years After Zephyr First Failure

 
• By Reed Miller

Pulmonx is almost ready to submit the results of the pivotal LIBERATE trial of its Zephyr endobronchial valve to the US FDA. The data will support a premarket approval and the company hopes to bring the device, along with the Chartis patient-selection system, to the US market in 2018.

Lungs
Pulmonx set to enter US market with endobronchial valve

More from Respiratory

More from Device Area